Integra Lifesciences Holdings Corp (NASDAQ:IART) major shareholder Richard E. Caruso sold 32,880 shares of the stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $53.68, for a total value of $1,764,998.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Integra Lifesciences Holdings Corp (NASDAQ IART) opened at $56.23 on Wednesday. The stock has a market capitalization of $4,305.41, a price-to-earnings ratio of 68.57, a PEG ratio of 1.69 and a beta of 0.65. Integra Lifesciences Holdings Corp has a 52 week low of $40.51 and a 52 week high of $56.42. The company has a quick ratio of 1.51, a current ratio of 2.36 and a debt-to-equity ratio of 1.85.

How to Become a New Pot Stock Millionaire

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.08. The firm had revenue of $368.60 million for the quarter, compared to the consensus estimate of $362.64 million. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. During the same period last year, the business posted $0.52 EPS. research analysts predict that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current year.

Several brokerages have commented on IART. Oppenheimer reiterated a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, January 11th. JMP Securities increased their target price on Integra Lifesciences from $57.00 to $60.00 and gave the company a “market outperform” rating in a research note on Wednesday, February 28th. Jefferies Group reiterated a “buy” rating and set a $63.00 target price on shares of Integra Lifesciences in a research note on Thursday, March 1st. TheStreet upgraded Integra Lifesciences from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Finally, BidaskClub upgraded Integra Lifesciences from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $54.18.

Several hedge funds have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB purchased a new position in shares of Integra Lifesciences in the 4th quarter worth $311,000. Segall Bryant & Hamill LLC boosted its stake in shares of Integra Lifesciences by 12.0% in the 4th quarter. Segall Bryant & Hamill LLC now owns 125,992 shares of the life sciences company’s stock worth $6,030,000 after buying an additional 13,472 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Integra Lifesciences in the 4th quarter worth $1,390,000. Gotham Asset Management LLC purchased a new position in shares of Integra Lifesciences in the 4th quarter worth $3,453,000. Finally, Meadow Creek Investment Management LLC boosted its stake in shares of Integra Lifesciences by 23.9% in the 4th quarter. Meadow Creek Investment Management LLC now owns 8,568 shares of the life sciences company’s stock worth $410,000 after buying an additional 1,652 shares during the last quarter. Hedge funds and other institutional investors own 90.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/03/14/integra-lifesciences-holdings-corp-iart-major-shareholder-richard-e-caruso-sells-32880-shares.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.